한글목차

시장 개요

세계의 악성중피종 치료 시장은 2022년에 2억 5,930만 달러에 달하며, 2030년에는 최대 5억 1,270만 달러에 달할 것으로 예상됩니다. 세계의 악성중피종 치료는 예측 기간(2023-2030년) 동안 9.1%의 CAGR을 보일 것으로 예상됩니다.

악성중피종 환자 수 증가, 암 치료에 대한 인식 증가, 다양한 산업에서 석면 사용 확대, 기술 혁신 확대 등 주요 산업 촉진요인이 시장 확대를 지원할 것으로 예상됩니다.

예측 기간 중 세계 악성중피종 치료 시장은 고급 치료법의 가용성으로부터 혜택을 받을 것으로 예상됩니다. 또한 악성중피종 치료 세계 시장은 중피종 형성의 주요 원인인 다양한 제품 및 분야의 석면에 의해 주도될 것으로 보입니다.

시장 역학

조기진단 및 조기치료에 대한 인식개선 활동 활성화가 시장 성장을 견인

악성중피종은 세계에서 널리 퍼져 있으며, 조기 진단과 조기 치료를 위한 인식 개선이 필요합니다. 많은 단체들이 이 질환에 대한 인식을 높이고 석면에 노출된 직원들이 악성중피종에 대한 선별 검사를 자주 받도록 권장하고 있으며, 이를 통해 질환의 진행을 예방할 수 있습니다. 이러한 인식 증가는 전체 시장 성장에 긍정적인 영향을 미칠 것으로 예상됩니다.

또한 담배와 흡연의 소비 증가는 악성중피종 치료 시장을 발전시킬 것입니다. 세계 악성중피종 시장의 대부분의 기업은 악성중피종에 대한 여러 약물 조합의 효과를 탐구하기 위해 조직과 협력하고 있습니다. 기술 특허가 부족하기 때문에 많은 기업들이 다양한 약물 조합에 초점을 맞춘 임상 연구를 수행하고 있습니다.

악성중피종의 긴 잠복기가 시장 성장의 걸림돌로 작용할 가능성이 높습니다.

악성중피종의 긴 잠복기, 초기 단계의 질병 특이적 바이오마커의 부족, 암 치료를 위한 혁신적인 장비의 개발 및 승인은 예측 기간 중 악성중피종 치료 시장의 성장을 둔화시킬 수 있습니다.

COVID-19의 영향 분석

악성중피종 치료제 세계 시장은 COVID-19 팬데믹으로 인해 여러 부문에서 의약품 수요가 증가했으며, COVID-19 상황과 관련하여 여러 부문에서 의약품 수요가 증가했습니다. 이 업계의 제약 회사들은 공급망 관리를 크게 개선하고, 연구개발 능력을 향상시키고, 제조 관리 및 품질 관리에 대한 투자를 늘리고 있습니다.

목차

제1장 조사 방법과 범위

• 조사 방법
• 조사 목적 및 조사 범위

제2장 정의와 개요

제3장 주요 요약

• 약물 클래스별 스니펫
• 투여 경로별 스니펫
• 최종사용자별 스니펫

제4장 시장 역학

• 영향요인
  • 촉진요인
  • 억제요인
    • 악성중피종의 긴 잠복 기간
  • 기회
    • 첨단기술의 채택이 증가
  • 영향 분석

제5장 산업 분석

• Porter's Five Forces 분석
• 공급망 분석
• 가격 분석
• 법규제 분석

제6장 COVID-19의 분석

제7장 약제 유형별

• Pemetrexed
• Cisplatin
• Carboplatin
• Gemcitabine
• Vinorelbine
• 기타

제8장 투여 경로별

• 경구
• 비경구

제9장 투여 경로별

• 병원
• 암센터
• 기타

제10장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미 지역
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 호주
  • 기타 아시아태평양
• 중동 및 아프리카

제11장 경쟁 구도

• 경쟁 시나리오
• 시장 현황/점유율 분석
• M&A(합병·인수) 분석

제12장 기업 개요

• Dr. Reddy's Laboratories,
• Wellona Pharmaceuticals
• Bristol-Myers Squibb
• Novocure
• Eli Lilly and Company
• Merck
• Manus Aktteva Biopharma LLP
• Pfizer
• Ono Pharmaceuticals

제13장 부록

영문목차

Market Overview

The Global Malignant Mesothelioma Therapeutics Market reached US$ 259.3 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 512.7 million by 2030. The global malignant mesothelioma therapeutics is expected to exhibit a CAGR of 9.1% during the forecast period (2023-2030).

The main industry drivers, including the rise in malignant mesothelioma instances, rising cancer treatment awareness, expanding use of asbestos in a variety of industries, and expanding technical breakthroughs, are anticipated to support market expansion.

Over the projected period, the global malignant mesothelioma therapeutics market is expected to benefit from the availability of sophisticated treatments. Furthermore, the global market for malignant mesothelioma therapeutics is likely to be driven by asbestos in various products and sectors, which is a key cause of mesothelioma formation.

Market Dynamics

Increased Awareness Campaigns to Diagnose and Treat the Disease at an Earlier Stage will Drive the Market Growth

Malignant mesothelioma is becoming more common worldwide, necessitating increased awareness campaigns to diagnose and treat the disease at an earlier stage. Many groups are raising awareness about the condition and recommending that asbestos-exposed employees get frequent screenings for malignant mesothelioma, which can help prevent the disease from progressing to advanced stages. This increased awareness is projected to impact market growth overall positively.

Furthermore, rising tobacco and smoking consumption propel the malignant mesothelioma therapeutics market forward. The majority of firms in the global malignant mesothelioma market are working with organizations to explore the effects of combining numerous medications on malignant mesothelioma. Due to the scarcity of technique patents, numerous companies are conducting clinical studies focusing on various combination medications.

The Long Latency Period For Malignant Mesothelioma Is Likely To Hamper The Market Growth

A long latency period for malignant mesothelioma, a lack of disease-specific biomarkers in the early stages, and the development and approval of innovative devices for cancer treatment may slow the growth of the malignant mesothelioma therapeutics market throughout the projection period.

COVID-19 Impact Analysis

The global market for malignant mesothelioma therapeutics has benefited from the COVID-19 outbreak. About the COVID-19 situation, several segments have seen an increase in drug demand. Pharmaceutical businesses in this industry have greatly improved their supply chain management, increased their R&D skills, and increased their manufacturing management and quality control investments.

Segment Analysis

Pemetrexed Drug in Drug Class Segment will Dominate in the Market by Capturing 39.1% During the Forecast Period

The preference for combination medicines over monotherapy is one of the key factors that positively influence the Pemetrexed and combination drug type sector. Combination therapies, such as chemotherapy combined with radiation, targeted antibodies, cryotherapy, or other immunotherapies, are anticipated to expand the potential indications for various drugs.

These combination therapies aim to improve survival rates significantly, as evidenced by limited clinical data compared to only surgeries or radiation therapies. Several companies have discovered that multiple pathways in tumor regulation are affected, and as a result, they seek to use combination therapy as a more effective method. These factors are likely to boost the malignant mesothelioma therapeutics market.

Geographical Analysis

North America is the Dominating Region During the Forecast Period

In 2022, the United States is a key participant in this region, accounting for approximately 39.2% of the market. Because of increased awareness about risk factors and diagnostic procedures, the malignant mesothelioma market size in North America is growing faster than in other areas. Advanced healthcare infrastructure is also expected to drive and contribute to the growth of the malignant mesothelioma therapeutics market in North America.

Competitive Landscape

The major global players include: Dr. Reddy's Laboratories, Wellona Pharmaceuticals, Bristol-Myers Squibb, Novocure, Eli Lilly and Company, Merck, Manus Aktteva Biopharma LLP, Pfizer and Ono Pharmaceuticals.

• Why Purchase the Report?
• To visualize the global malignant mesothelioma therapeutics market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of malignant mesothelioma therapeutics market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The malignant mesothelioma therapeutics market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by End user

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers

Increased awareness campaigns to diagnose and treat the disease at an earlier stage

• 4.1.2. Restraints
  • 4.1.2.1. The long latency period for malignant mesothelioma
• 4.1.3. Opportunity
  • 4.1.3.1. Increasing adoption of advanced technologies
• 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Drug Type

• 7.1. Pemetrexed
• 7.2. Cisplatin
• 7.3. Carboplatin
• 7.4. Gemcitabine
• 7.5. Vinorelbine
• 7.6. Others

8. By Route of Administration

• 8.1. Oral
• 8.2. Parenteral

9. By Route of Administration

• 9.1 Hospitals
• 9.2 Cancer Centers
• 9.3 Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%) By End User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Use
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Dr. Reddy's Laboratories,
• 12.2. Wellona Pharmaceuticals
• 12.3. Bristol-Myers Squibb
• 12.4. Novocure
• 12.5. Eli Lilly and Company
• 12.6. Merck
• 12.7. Manus Aktteva Biopharma LLP
• 12.8. Pfizer
• 12.9. Ono Pharmaceuticals

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us